Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Aptinyx Inc (APTX)

Aptinyx Inc (APTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Canada’s Apotex Reports Net Loss After Going Public Baystreet - Wed Aug 12, 8:41AM CDT

Canadian pharmaceutical company Apotex Health Corp. (TSE: APTX) has reported a net loss in its first ...

APTX.TO : 35.51 (-0.56%)
APTX : 0.0960 (+3.11%)
Aptinyx Reports on Fourth Quarter and Full Year 2022 Results and Highlights and Review of Strategic Alternatives Business Wire - Thu Mar 30, 2023

Aptinyx Inc. (Nasdaq: APTX) today reported recent business updates and financial results for the fourth quarter and full year 2022.

APTX : 0.0960 (+3.11%)
Wall Street - New York Stock Exchange NYSE
Stocks Mixed Before The Open As Fed Fears Persist, Target Earnings On Tap Barchart - Tue Feb 28, 2023

March S&P 500 futures (ESH23) are trending up +0.07% this morning after three major U.S. benchmark indices ended the regular session higher as investors digested an early round of U.S. economic data and...

TGT : 156.33 (+1.51%)
BAYN.D.DX : 47.985 (-0.05%)
MNST : 46.58 (+1.30%)
HIMS : 29.42 (-1.84%)
PGNY : 25.87 (+1.77%)
ESH23 : 3,957.05s (-0.09%)
HPQ : 29.64 (+1.23%)
RIVN : 15.94 (+0.06%)
WDAY : 178.63 (+1.91%)
APTX : 0.0960 (+3.11%)
TSLA : 333.18 (+1.73%)
ZM : 105.78 (+0.62%)
Aptinyx Reports Results from Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson's Disease and Dementia with Lewy Bodies and Provides Pipeline and Corporate Update Business Wire - Mon Feb 27, 2023

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced results from a Phase...

APTX : 0.0960 (+3.11%)
Aptinyx to Present at the SVB Securities Global Biopharma Conference Business Wire - Tue Jan 31, 2023

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Andy Kidd, M.D.,...

APTX : 0.0960 (+3.11%)
Preclinical Data from Aptinyx’s NMDA Receptor Modulators to be Presented at the 52nd Annual Meeting of the Society for Neuroscience Business Wire - Thu Nov 10, 2022

Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced upcoming poster presentations...

APTX : 0.0960 (+3.11%)
Aptinyx Reports Third Quarter 2022 Financial Results and Recent Highlights Business Wire - Tue Nov 8, 2022

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for...

APTX : 0.0960 (+3.11%)
Clinical Evaluation of Aptinyx's NYX-783 for Treatment of Opioid Use Disorder to Be Funded by $5.6 Million NIH Grant Business Wire - Thu Nov 3, 2022

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced the finalization of a $5.6 million...

APTX : 0.0960 (+3.11%)
Aptinyx to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022 Business Wire - Tue Oct 18, 2022

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will...

APTX : 0.0960 (+3.11%)
Aptinyx Completes Enrollment in Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson’s Disease and Dementia with Lewy Bodies Business Wire - Thu Aug 25, 2022

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the completion of enrollment...

APTX : 0.0960 (+3.11%)

Barchart Exclusives

Ugly STMicroelectronics Stock May Have Just Signaled a Turnaround Barchart - 3 minutes ago
While the proposition is a high-risk, high-reward opportunity, there’s a rational basis for targeting STM stock for potential upside. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.